Literature DB >> 25371175

Classifying ultra-high risk smoldering myeloma.

A J Waxman1, R Mick2, A L Garfall1, A Cohen1, D T Vogl1, E A Stadtmauer1, B M Weiss1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25371175     DOI： 10.1038/leu.2014.313

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

1.  Diagnosis of smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Dirk Larson; Robert A Kyle
Journal:  N Engl J Med       Date:  2011-08-04       Impact factor: 91.245

2.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

3.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

4.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

5.  A monoclonal gammopathy precedes multiple myeloma in most patients.

Authors:  Brendan M Weiss; Jude Abadie; Pramvir Verma; Robin S Howard; W Michael Kuehl
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

6.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

7.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

8.  Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.

Authors:  Angela Dispenzieri; Robert A Kyle; Jerry A Katzmann; Terry M Therneau; Dirk Larson; Joanne Benson; Raynell J Clark; L Joseph Melton; Morie A Gertz; Shaji K Kumar; Rafael Fonseca; Diane F Jelinek; S Vincent Rajkumar
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

9.  Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.

Authors:  Kai Neben; Anna Jauch; Thomas Hielscher; Jens Hillengass; Nicola Lehners; Anja Seckinger; Martin Granzow; Marc S Raab; Anthony D Ho; Hartmut Goldschmidt; Dirk Hose
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544

10.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.

Authors:  S V Rajkumar; V Gupta; R Fonseca; A Dispenzieri; W I Gonsalves; D Larson; R P Ketterling; J A Lust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2013-03-21       Impact factor: 11.528
View more
  8 in total

1.  Timing of treatment of smoldering myeloma: delay until progression.

Authors:  Shaji K Kumar
Journal:  Blood Adv       Date:  2018-11-13

2.  Timing of treatment of smoldering myeloma: early treatment.

Authors:  María-Victoria Mateos; Verónica González-Calle
Journal:  Blood Adv       Date:  2018-11-13

3.  Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.

Authors:  Vernon Wu; Erin Moshier; Siyang Leng; Bart Barlogie; Hearn Jay Cho; Sundar Jagannath; Deepu Madduri; Madhu Mazumdar; Samir Parekh; Ajai Chari
Journal:  Blood Adv       Date:  2018-06-26

4.  Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

Authors:  V González-Calle; J Dávila; F Escalante; A G de Coca; C Aguilera; R López; A Bárez; J M Alonso; R Hernández; J M Hernández; P de la Fuente; N Puig; E M Ocio; N C Gutiérrez; R García-Sanz; M V Mateos
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

5.  Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies.

Authors:  Ai-Lin Zhao; Kai-Ni Shen; Ji-Nuo Wang; Lan-Qing Huo; Jian Li; Xin-Xin Cao
Journal:  Cancer Manag Res       Date:  2019-06-21       Impact factor: 3.989

Review 6.  Risk Stratification and Treatment in Smoldering Multiple Myeloma.

Authors:  Tyler Lussier; Natalie Schoebe; Sabine Mai
Journal:  Cells       Date:  2021-12-31       Impact factor: 6.600

7.  Gamma gap thresholds and HIV, hepatitis C, and monoclonal gammopathy.

Authors:  Gigi Y Liu; Olive Tang; Daniel J Brotman; Edgar R Miller; Alison R Moliterno; Stephen P Juraschek
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

Review 8.  2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.

Authors:  Pellegrino Musto; Monika Engelhardt; Jo Caers; Niccolo' Bolli; Martin Kaiser; Niels Van de Donk; Evangelos Terpos; Annemiek Broijl; Carlos Fernández De Larrea; Francesca Gay; Hartmut Goldschmidt; Roman Hajek; Annette Juul Vangsted; Elena Zamagni; Sonja Zweegman; Michele Cavo; Meletios Dimopoulos; Hermann Einsele; Heinz Ludwig; Giovanni Barosi; Mario Boccadoro; Maria-Victoria Mateos; Pieter Sonneveld; Jesus San Miguel
Journal:  Haematologica       Date:  2021-11-01       Impact factor: 9.941
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.